{"id":850840,"date":"2025-05-14T08:04:08","date_gmt":"2025-05-14T12:04:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\/"},"modified":"2025-05-14T08:04:08","modified_gmt":"2025-05-14T12:04:08","slug":"lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\/","title":{"rendered":"Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC"},"content":{"rendered":"

<\/p>\n

Lineage to Present at 3rd<\/sup> Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC<\/b><\/p>\n

CARLSBAD, Calif.–(BUSINESS WIRE<\/a>)–Lineage Cell Therapeutics, Inc.<\/a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage\u2019s Chief Executive Officer, will be presenting at the 3rd<\/sup> Annual H.C. Wainwright BioConnect Investor Conference<\/a>, in a fireside chat hosted by Joseph Pantginis, Ph.D., Managing Director, Equity Research, on Tuesday, May 20, 2025, at 2:30pm ET. The 3rd<\/sup> Annual H.C. Wainwright BioConnect Investor Conference takes place on Tuesday, May 20, 2025, at the Nasdaq stock exchange headquarters in New York, NY.\n<\/p>\n

\nInvestors interested in scheduling an in-person meeting with the Lineage management team should contact their H.C. Wainwright representative or email meetings@hcwco.com<\/a>. A replay of Lineage\u2019s fireside chat will be available on the Events and Presentations<\/a> section of Lineage\u2019s website, following the conclusion of the conference.\n<\/p>\n

About Lineage Cell Therapeutics, Inc.<\/b><\/p>\n

\nLineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, \u201coff-the-shelf,\u201d cell therapies to address unmet medical needs. Lineage\u2019s programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient\u2019s functional activity. Lineage\u2019s neuroscience focused pipeline currently includes: (i) OpRegen\u00ae<\/sup>, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1\/2a development for the treatment of spinal cord injuries; (iii) ReSonance\u2122 (ANP1), an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed under a gene editing partnership. For more information, please visit www.lineagecell.com<\/a> or follow the company on X\/Twitter @LineageCell<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250514299171\/en\/<\/a><\/span><\/p>\n

Lineage Cell Therapeutics, Inc. IR
\n<\/b>
Ioana C. Hone
\n
(ir@lineagecell.com<\/a>)
\n
(442) 287-8963\n<\/p>\n

Russo Partners \u2013 Media Relations
\n<\/b>
Nic Johnson or David Schull
\n
(Nic.johnson@russopartnersllc.com<\/a>)
\n
(David.schull@russopartnersllc.com<\/a>)
\n
(212) 845-4242\n<\/p>\n

KEYWORDS:<\/b> United States North America California New York<\/p>\n

INDUSTRY KEYWORDS:<\/b> Science Neurology Biotechnology Research General Health Health Genetics Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC CARLSBAD, Calif.–(BUSINESS WIRE)–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage\u2019s Chief Executive Officer, will be presenting at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, in a fireside chat hosted by Joseph Pantginis, Ph.D., Managing Director, Equity Research, on Tuesday, May 20, 2025, at 2:30pm ET. The 3rd Annual H.C. Wainwright BioConnect Investor Conference takes place on Tuesday, May 20, 2025, at the Nasdaq stock exchange headquarters in New York, NY. Investors interested in scheduling an in-person meeting with the Lineage management team should contact their … <\/p>\n

Continue reading “Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-850840","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC CARLSBAD, Calif.–(BUSINESS WIRE)–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage\u2019s Chief Executive Officer, will be presenting at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, in a fireside chat hosted by Joseph Pantginis, Ph.D., Managing Director, Equity Research, on Tuesday, May 20, 2025, at 2:30pm ET. The 3rd Annual H.C. Wainwright BioConnect Investor Conference takes place on Tuesday, May 20, 2025, at the Nasdaq stock exchange headquarters in New York, NY. Investors interested in scheduling an in-person meeting with the Lineage management team should contact their … Continue reading "Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-14T12:04:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250514299171r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC\",\"datePublished\":\"2025-05-14T12:04:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\\\/\"},\"wordCount\":509,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250514299171r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\\\/\",\"name\":\"Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250514299171r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-05-14T12:04:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250514299171r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250514299171r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\/","og_locale":"en_US","og_type":"article","og_title":"Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC - Market Newsdesk","og_description":"Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC CARLSBAD, Calif.–(BUSINESS WIRE)–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage\u2019s Chief Executive Officer, will be presenting at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, in a fireside chat hosted by Joseph Pantginis, Ph.D., Managing Director, Equity Research, on Tuesday, May 20, 2025, at 2:30pm ET. The 3rd Annual H.C. Wainwright BioConnect Investor Conference takes place on Tuesday, May 20, 2025, at the Nasdaq stock exchange headquarters in New York, NY. Investors interested in scheduling an in-person meeting with the Lineage management team should contact their … Continue reading \"Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-14T12:04:08+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250514299171r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC","datePublished":"2025-05-14T12:04:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\/"},"wordCount":509,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250514299171r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\/","name":"Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250514299171r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-05-14T12:04:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250514299171r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250514299171r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-3rd-annual-h-c-wainwright-bioconnect-investor-conference-at-nasdaq-nyc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/850840","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=850840"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/850840\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=850840"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=850840"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=850840"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}